Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate (2007-5904)

Phase II Study to Determine the Effects of Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate in Patients Who Are Scheduled for Radical Prostatectomy With Genomic Correlates of Pathological Response

This pilot phase II trial studies docetaxel and prednisone in treating patients with newly diagnosed stage I-II prostate cancer undergoing prostatectomy. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as prednisone, may stimulate the immune system in different ways and stop cancer cells from growing. Giving docetaxel and prednisone together may kill more tumor cells.

Study Overview

• Status: Withdrawn
• Conditions: Prostate Cancer; Stage I Prostate Cancer; Stage II Prostate Cancer; Adenocarcinoma of the Prostate
• Intervention / Treatment: Drug: Docetaxel; Drug: Prednisone

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the rate of a 3-month prostate-specific antigen (PSA) decline of at least 30% by chemotherapy regimen of docetaxel and prednisone in patients with stage I/II prostate cancer, who are scheduled for prostatectomy.

II. To compare tumor, pathological and PSA responses to neoadjuvant docetaxel between patients with intermediate and high grades of prostate cancer.

III. To obtain prostate specimens for genomic correlates with responses of the chemotherapy regimen of docetaxel and prednisone.

OUTLINE:

Patients receive docetaxel intravenously (IV) over 60 minutes on days 1 and 2 and prednisone orally (PO) twice daily (BID) on days 1-21. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy within 3 weeks after completion of chemotherapy.

After completion of study treatment, patients are followed up within 7 days.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Patient must have a histological diagnosis of adenocarcinoma of the prostate which is measurable or evaluable Stage I or II.
• Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Patient must have a pre-study PSA within 28 days prior to start of therapy.
• Patients who have received prior radiotherapy are not eligible.
• Patient must have an adequate renal function
• Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
• Age > 18
• Patients must be able to take oral medications

Exclusion Criteria:

• Patients with measurable metastatic diseases by a CT scan of the abdomen and pelvis within 28 days and by a bone scan within 42 days prior to start of therapy.
• Patient must not have received chemotherapy, biologic therapy or any other investigational drug for any reason within 28 days prior to start of therapy and must have recovered from toxicities of prior therapy to grade 1 or less with the exception of alopecia.
• Patients must not be treated with non-steroidal anti-androgens (flutamide, bicalutamide, nilutamide or ketoconazole).
• Patients must not take vitamins, herbs, or micronutrient supplement within 28 days prior to start of therapy.
• Patients may not have ongoing problems with bowel obstruction or short bowel syndrome characterized by grade 2 or greater diarrhea or malabsorptive disorders.
• Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80
• Patients should not have psychological, familial, sociological, or geographical conditions that do not permit medical follow-up or compliance with the study protocol.
• Patients should not have any medical life-threatening complications of their malignancies
• Patients should not have a known severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, active uncontrolled infection, or HIV).
• Patients should not have current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study.
• Patients with history of myocardial infarction, cerebrovascular accident, transient ischemic attack, or unstable angina within 6 months
• Patients with clinically significant peripheral vascular disease
• Patients with evidence of bleeding diathesis or coagulopathy
• Patients with central nervous system or brain metastases
• Patients who had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
• Patients with minor surgical procedures, fine needle aspirations or core biopsies within 7 days prior to Day 0
• Patients with history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
• Patients with serious, non-healing wound, ulcer, or bone
• Patients who are diagnosed of any other malignancy except non-melanomatous skin cancer in the past 5 years
• Patients receiving anticoagulation therapy (e.g. Coumadin) prior to registration

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (docetaxel and prednisone); Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Drug: Docetaxel; Given IV; Other Names: Taxotere; RP56976; RP 56976; TXT; 114977-28-5; 40466; 628503; Drug: Prednisone; Given PO; Other Names: Orasone; Adasone; Cortancyl; Dacortin; DeCortin; Decortisyl; Decorton; Delta-Dome; Deltacortene; Deltison; Deltra; Econosone; Lisacort; Meprosona-F; Meticorten; Ofisolona; Panafcort; Panasol-S; Paracort; PRED; Predicor; Predicorten; Prednicen-M; Prednicort; Prednidib; Prednilonga; Predniment; Prednisonum; Prednitone; Promifen; Servisone; Liquid Pred; Sterapred; PRD; metacortandracin; deltacortisone; deltadehydrocortisone; Delta(1)-Cortisone; Predeltin; Sk-Prednisone

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PSA response rate (partial response (PR) + complete response (CR))	Expressed with two-sided exact binomial confidence intervals. Significance of changes between pre- and after-treatment PSA or testosterone will be determined by the Wilcoxon signed-rank test. The difference of response rates between different pre-treatment pathological stages or Gleason scores will also be examined by Fisher's exact test. Associations between PSA response and tumor response, and PSA response and gene expression will also be examined by Fisher's exact test.	9 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rates of tumor response	Expressed with two-sided exact binomial confidence intervals.	Up to 7 days after completion of study treatment
The rate of negative surgical margin		Up to 7 days after completion of study treatment
The proportion of patients with pathological down-staging defined as evidence of decreased pathological stage or Gleason score when compared with pretreatment pathological stage		Up to 7 days after completion of study treatment
Adverse events defined as any untoward medical occurrence in a patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment	Severity will be categorized by toxicity grade according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.	Up to 28 days after completion of study treatment

Collaborators and Investigators

• Sponsor: John P. Fruehauf
• Collaborators: Sanofi

Study record dates

Study Major Dates

• Study Start: January 1, 2009
• Primary Completion (Actual): June 1, 2010
• Study Completion (Actual): June 1, 2010

Study Registration Dates

• First Submitted: January 10, 2008
• First Submitted That Met QC Criteria: January 10, 2008
• First Posted (Estimate): January 23, 2008

Study Record Updates

• Last Update Posted (Estimate): December 8, 2016
• Last Update Submitted That Met QC Criteria: December 6, 2016
• Last Verified: April 1, 2013

More Information

Terms related to this study

• Keywords: prostate cancer; Prostatectomy
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Male; Prostatic Diseases; Prostatic Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Docetaxel; Prednisone; Cortisone
• Other Study ID Numbers: UCI 07-14; 2007-5904 (Other Identifier: University of California, Irvine); NCI-2012-02085 (Other Identifier: NCI Clinical Trials Reporting Program (CTRP))